These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 30036258

  • 1. Schmorl's Node: Confusion Still Persists in 68Ga-Prostate-Specific Membrane Antigen Ligand PET/CT.
    Sahoo MK, Ahlawat K, Yadav R, Gajendra S.
    Clin Nucl Med; 2018 Sep; 43(9):679-681. PubMed ID: 30036258
    [Abstract] [Full Text] [Related]

  • 2. Early Detection of Bilateral Testicular Metastases From Prostatic Adenocarcinoma Using 68Ga-PSMA Ligand PET/CT.
    Weiberg D, Radner H, Derlin T, Thon WF.
    Clin Nucl Med; 2017 Jul; 42(7):563-564. PubMed ID: 28368893
    [Abstract] [Full Text] [Related]

  • 3. Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.
    Rauscher I, Maurer T, Steiger K, Schwaiger M, Eiber M.
    Clin Nucl Med; 2017 Jul; 42(7):547-548. PubMed ID: 28368889
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
    Acar E, Bekiş R, Polack B.
    Curr Med Imaging Rev; 2019 Jul; 15(6):589-594. PubMed ID: 32008568
    [Abstract] [Full Text] [Related]

  • 7. An 18F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with 18F-JK-PSMA-7 During the First Year of Application.
    Dietlein F, Hohberg M, Kobe C, Zlatopolskiy BD, Krapf P, Endepols H, Täger P, Hammes J, Heidenreich A, Neumaier B, Drzezga A, Dietlein M.
    J Nucl Med; 2020 Feb; 61(2):202-209. PubMed ID: 31324713
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.
    Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA.
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [Abstract] [Full Text] [Related]

  • 12. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
    Verma P, Malhotra G, Meshram V, Chandak A, Sonavane S, Lila AR, Bandgar TR, Asopa RV.
    Clin Nucl Med; 2021 Aug 01; 46(8):e406-e409. PubMed ID: 33883490
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug 01; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
    Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, Halac M, Talat Z, Araman A.
    Nucl Med Commun; 2015 Jun 01; 36(6):582-7. PubMed ID: 25738559
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
    Hofman MS, Hicks RJ, Maurer T, Eiber M.
    Radiographics; 2018 Jun 01; 38(1):200-217. PubMed ID: 29320333
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer.
    Aragon-Ching JB.
    Asian J Androl; 2021 Jun 01; 23(1):1-2. PubMed ID: 32719192
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.